dimercaprol has been researched along with Abnormalities, Drug-Induced in 4 studies
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.
dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There were no maternal toxic effects, and no treatment-related changes were recorded in the number of total implants, resorption, the number of live and dead fetuses, fetal body weight or fetal sex distribution data." | 1.28 | Evaluation of the developmental toxicity of 2,3-dimercapto-1-propanesulfonate (DMPS) in mice. Effect on mineral metabolism. ( Bosque, MA; Corbella, J; Domingo, JL; Llobet, JM; Paternain, JL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomez, M | 1 |
| Sanchez, DJ | 1 |
| Colomina, MT | 1 |
| Domingo, JL | 2 |
| Corbella, J | 2 |
| Hood, RD | 2 |
| Thacker, GT | 1 |
| Patterson, BL | 1 |
| Bosque, MA | 1 |
| Paternain, JL | 1 |
| Llobet, JM | 1 |
| Pike, CT | 1 |
4 other studies available for dimercaprol and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Evaluation of the protective activity of 2,3-dimercaptopropanol and sodium 2,3-dimercaptopropane-1-sulfonate on methylmercury-induced developmental toxicity in mice.
Topics: Abnormalities, Drug-Induced; Animals; Dimercaprol; Female; Fetus; Methylmercury Compounds; Mice; Pre | 1994 |
Effects in the mouse and rat of prenatal exposure to arsenic.
Topics: Abnormalities, Drug-Induced; Animals; Arsenic; Dimercaprol; Dose-Response Relationship, Drug; Female | 1977 |
Evaluation of the developmental toxicity of 2,3-dimercapto-1-propanesulfonate (DMPS) in mice. Effect on mineral metabolism.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Body Weight; Dimercaprol; Embryonic and | 1990 |
BAL alleviation of arsenate-induced teratogenesis in mice.
Topics: Abnormalities, Drug-Induced; Animals; Arsenic; Body Weight; Dimercaprol; Female; Fetal Death; Fetus; | 1972 |